Comparing the real-world effectiveness of botulinum toxin type A injections across distinct poststroke muscle hyper-resistance patterns - Report - MDSpire
Advertisement
Comparing the real-world effectiveness of botulinum toxin type A injections across distinct poststroke muscle hyper-resistance patterns
Clinical Report: Evaluating the Real-World Efficacy of Botulinum Toxin Type A Injections
Overview
This study evaluates the effectiveness of Botulinum Toxin Type A (BoNT-A) injections in stroke survivors with muscle hyper-resistance, comparing outcomes between those with spasticity alone and those with spasticity accompanied by contracture. Results indicate that both groups show improvement.
Background
Post-stroke muscle hyper-resistance, which includes both neurogenic spasticity and non-neurogenic contracture, is a significant barrier to rehabilitation and recovery. Effective management of these conditions is crucial.
Data Highlights
Group
Baseline Characteristics
Improvement at 12 Weeks
Spasticity Group
54 patients, PROM limitation <7°
Improved MAS, BRS, FMA, BI
Spasticity with Contracture Group
53 patients, PROM limitation ≥7°
Improved MAS, BRS (only at 12 weeks)
Key Findings
Both groups showed improvements in MAS and BRS at all follow-up visits.
The spasticity group had significantly better MAS and BRS scores at each time point compared to the spasticity-with-contracture group.
FMA and BI scores improved in the spasticity group at 4 and 12 weeks, while the spasticity-with-contracture group showed improvement only at 12 weeks.
Longer disease duration was noted in the spasticity-with-contracture group at baseline.
Median FMA and BI were numerically higher in the spasticity group, but differences did not reach statistical significance.
Clinical Implications
The findings indicate that BoNT-A is effective in reducing post-stroke hyper-resistance.
Conclusion
BoNT-A injections are effective in managing post-stroke hyper-resistance.
